Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy
Cancers · 25.03.2026 · 18 (7) · 1070
DOI: 10.3390/cancers18071070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 25.03.2026. Verfasst von Cirino Botta und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90100 Palermo, Italy. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer (Italy).
Abstract (Originalsprache)
Background
Multiple myeloma remains an incurable malignancy in which patients ultimately experience relapses and refractory disease despite therapeutic advances. Triple-class exposed relapsed/refractory MM (TCE/RRMM) patients represent both a population with high unmet clinical needs and a substantial economic burden for the Italian National Health Service (NHS). Recently, BCMA-CD3 bispecific antibodies, including elranatamab and teclistamab, have expanded the treatment options for these patients. This study aimed to evaluate the cost-effectiveness of elranatamab versus teclistamab in adults with TCE/RRMM from the Italian NHS perspective.
Methods
A partitioned survival model with three health states—progression-free survival, post-progression survival, and death—was developed over a 25-year lifetime horizon, adopting weekly cycles and a 3% annual discount rate. Clinical data for elranatamab were derived from the MagnetisMM-3 trial, while teclistamab outcomes were estimated through matching-adjusted indirect comparisons using MajesTEC-1 data. Direct medical costs included those associated with drug acquisition and administration, disease management, adverse event management, and end-of-life care. Utility values were obtained from EQ-5D-based assessments in MagnetisMM-3. Deterministic and probabilistic sensitivity analyses were performed to test model robustness.
Results
Elranatamab yielded 3.31 life-years and 2.33 QALYs per patient, compared with 1.83 life-years and 1.27 QALYs for teclistamab. Total lifetime costs were lower for elranatamab (EUR 153,337) versus teclistamab (EUR 224,610), generating EUR 71,273 in savings. Thus, elranatamab is considered to be dominant, due to its higher efficacy and lower cost. Furthermore, the robustness of these findings was confirmed through sensitivity analyses.
Conclusions
From the Italian NHS perspective, elranatamab represents a clinically superior and economically favorable option for patients with TCE/RRMM. The obtained results support its value and sustainability within the national treatment landscape.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90100 Palermo, Italy.
- Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
- CEFAT-Center of Pharmaceuticals Economics and Medical Technologies Evaluation, Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
- Center of Research, SAVE Studi-Health Economics and Outcomes Research, 20100 Milan, Italy.
- Pfizer s.r.l., 00100 Rome, Italy.
- Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, 56100 Pisa, Italy.
ORCID-Profile: Cirino Botta, Giacomo Matteo Bruno, Sara Galimberti
Förderung
- Pfizer (Italy)
Zitieren
APA
Botta, C., Colombo, G. L., Di Matteo, S., Martinotti, C., Fogliati, E. L., Bruno, G. M., Novelli, G., Di Virgilio, R., Veggia, B., & Galimberti, S. (2026). Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy. Cancers, 18(7), 1070. https://doi.org/10.3390/cancers18071070
Vancouver
Botta C, Colombo GL, Di Matteo S, Martinotti C, Fogliati EL, Bruno GM, et al. Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy. Cancers. 2026;18(7):1070. doi:10.3390/cancers18071070
BibTeX
@article{Botta2026,
author = {Botta, Cirino and Colombo, Giorgio Lorenzo and Di Matteo, Sergio and Martinotti, Chiara and Fogliati, Emma Lucia and Bruno, Giacomo Matteo and Novelli, Giuseppe and Di Virgilio, Roberto and Veggia, Barbara and Galimberti, Sara},
title = {Cost-Effectiveness of Elranatamab Versus Teclistamab for the Management of Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in Italy},
journal = {Cancers},
year = {2026},
volume = {18},
number = {7},
pages = {1070},
doi = {10.3390/cancers18071070}
}
EUVIMED